CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis no differences from normal individuals and no relation to HLA-DR2

Journal of Neuroimmunology

Volumn 81, Issue 1-2, 1998, Pages 168-172

  Zipp, Frauke ^a   Faber, Efi ^a   Sommer, Norbert ^a   Müller, Claudia ^a   Dichgans, Johannes ^a   Krammer, Peter H ^b   Martin, Roland ^c   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

APO 1 antibody; Apoptosis; Autoimmune disease; CD95; HLA DR2; Multiple sclerosis; Peripheral blood mononuclear cells

Indexed keywords

FAS ANTIGEN; HLA DR ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; HLA TYPING; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD95; APOPTOSIS; AUTOIMMUNE DISEASES; DISEASE SUSCEPTIBILITY; GENE EXPRESSION; HLA-DR2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 0031809468     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00173-2     Document Type: Article

References (31)

1. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
2. Compston A., Sadovnick A.D. Epidemiology and Genetics of Multiple Sclerosis. Curr. Opinion Neurol. Neurosurgery. 5:1992;175-181.
3. Dowling P., Shang G., Raval S., Menonna J., Cook S., Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184:1996;1513-1518.
4. Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.L., Elkon K.B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1996;1643-1649.
5. D'Souza S.D., Bonetti B., Balasingam V., Cashman N.R., Barker P.A., Troutt A.B., Raine C.S., Antel J.P. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184:1996;2361-2370.
6. Ebers G.C., Sadovnick A.D. The role of genetic factors in multiple sclerosis susceptibility. J. Neuroimmunol. 54:1994;1-17.
7. Emlen W., Niebur J., Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 152:1994;3685-3692.
8. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middelton L.A., Lin A.Y., Strober W., Leonardo M.J., Puck J.M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935-946.
9. Goel N., Ulrich D.T., St. Clair E.W., Fleming J.A., Lynch D.H., Seldin M.F. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum. 38:1995;1738-1743.
10. Ichikawa H., Ota K., Iwata M. Increased Fas antigen on T cells in multiple sclerosis. J. Neuroimmunol. 71:1996;125-129.
11. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1992;1355-1364.
12. Klas C., Debatin K.M., Jonker R.R., Krammer P.H. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5:1993;625-630.
13. Knipping E., Krammer P.H., Onel K.B., Lehman T.J.A., Mysler E., Elkon K.B. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum. 38:1995;1735-1737.
14. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
15. Meinl E., Weber F., Drexler K., Morelle C., Ott M., Saruhan-Direskeneli G., Goebels N., Ertl B., Jechart G., Giegerich G., Schönbeck S., Bannwarth W., Wekerle H., Hohlfeld R. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J. Clin. Invest. 92:1993;2633-2643.
16. Miyawaki T., Uehara T., Nibu R., Tsuji T., Yachie A., Yonehara S., Taniguchi N. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149:1992;3753-3758.
17. Mysler E., Bini P., Drappa J., Ramos P., Friedman S.M., Krammer P.H., Elkon K.B. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J. Clin. Invest. 93:1994;1029-1034.
18. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
19. Nevinny-Stickel C., Bettinotti M.P., Andreas A., Hinzpeter M., Muhlegger K., Schmitz G., Albert E.D. Nonredioactive HLA class II typing using polymerase chain reaction and digoxigenin-11-2′-3′-dideoxy-uridinetriphosphate-labeled oligonucleatide probes. Hum. Immunol. 31:1991;7-13.
20. Oksenberg J.R., Begovich A.B., Steinman L. Genetic factors in multiple sclerosis. JAMA. 270:1993;2362-2369.
21. Olerup O., Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Ant. 38:1991;1-15.
22. Pagé B., Pagé M., Noel C. A new fluorometric assay for cytotoxicity measurements in vitro. Int. Oncol. 3:1993;473-476.
23. Pender M.P., Nguyen K.B., McCombe P.A., Kerr J.F.R. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J. Neurol. Sci. 104:1991;81-87.
24. Poser C.M., Paty D.W., Scheinberg L.e.a. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
25. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A.G., Debatin K.M., Fischer A., de Villartay J.P. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1995;1347-1349.
26. Schmied M., Breitschopf H., Gold R., Zischler H., Rothe G., Wekerle H., Lassmann H. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis: Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 143:1993;446-452.
27. Trauth B.C., Klas C., Peters A.M.J., Matzku S., Möller P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-305.
28. 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur. J. Immunol. 24:1994;1293-1300.
29. Weller M., Malipiero U., Rensing-Ehl A., Barr P.J., Fontana A. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res. 55:1995;2936-2944.
30. Zipp F., Weber F., Huber S., Sotgiu S., Czlonkowska A., Holler E., Albert E., Weiss E.H., Wekerle H., Hohlfeld R. Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor-a by HLA-DR2+ T cells. Ann. Neurol. 38:1995;723-730.
31. Zipp, F., Weller, M., Calabresi, P.A., Frank, J.A., Bash, C.N., Dichgans, J., McFarland, H., Martin, R., in press. Increased serum levels of soluble CD95 9APO1/Fas) in relapsing remiting multiple sclerosis. Ann. Neurol. in press.